Lanean...
AB110. Efficacy and safety of mTOR inhibitor in the treatment of renal cell cancer: a meta-analysis
BACKGROUND: Treatment for metastatic renal cell cancer (mRCC) has advanced dramatically with understanding of the pathogenesis of the disease. New treatment options may provide improved median progression-free survival (MPFS). We aimed to determine the relative effectiveness of new therapies in this...
Gorde:
| Argitaratua izan da: | Transl Androl Urol |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
AME Publishing Company
2014
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4708334/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2223-4683.2014.s110 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|